The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial
Background/Aims: Statin intolerance leads to poor adherence to statin therapy, resulting in a failure to achieve desired cholesterol reduction and adverse outcomes. The LILRB5 Asp247Gly genotype has been identified as being associated with statin intolerance and statin-induced myalgia. We conducted...
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Frontiers Media S.A.
2023-03-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1090010/full |